Akari Therapeutics (AKTX) Other Accumulated Expenses (2022 - 2026)
Akari Therapeutics (AKTX) reported Other Accumulated Expenses of $697000.0 for Q1 2026, up 44.01% on a YoY basis from $484000.0 in Q1 2025, and up 64.39% sequentially from $424000.0 in Q4 2025.
Akari Therapeutics (AKTX) Other Accumulated Expenses (2022 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 5 years of Other Accumulated Expenses data on file, last reported at $697000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 44.01% year-over-year to $697000.0; the trailing twelve-month figure through Mar 2026 stood at $697000.0 (up 44.01% YoY), and the FY2025 full-year result was $424000.0, down 42.0% from the prior year.
- Other Accumulated Expenses climbed to $697000.0 in Q1 2026, from $424000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $983000.0 in Q1 2024 to a low of $41000.0 in Q2 2024.
- A 5-year average of $396727.3 and a median of $424000.0 in 2025 frame the typical range for Other Accumulated Expenses.
- Peak annual rise in Other Accumulated Expenses reached 1485.37% in 2025, while the deepest fall reached 50.76% in 2025.
- Tracing AKTX's Other Accumulated Expenses over 5 years: stood at $94000.0 in 2022, then changed by 0.0% to $94000.0 in 2023, then soared by 677.66% to $731000.0 in 2024, then slumped by 42.0% to $424000.0 in 2025, then jumped by 64.39% to $697000.0 in 2026.
- Business Quant data shows AKTX's Other Accumulated Expenses at $697000.0 in Q1 2026, $424000.0 in Q4 2025, and $85000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 697,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 650,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Dec 31, 2024 | 731,000.00 |
| Sep 30, 2024 | 81,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Mar 31, 2024 | 983,000.00 |
| Dec 31, 2023 | 94,000.00 |
| Dec 31, 2022 | 94,000.00 |